EUR 309.30 For Business Accounts Only

Pharmaceuticals in Indonesia

Summary
Pharmaceuticals in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Indonesia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Indonesia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia pharmaceuticals market with five year forecasts

Synopsis
Essential resource for top-line data and analysis covering the Indonesia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buys

- What was the size of the Indonesia pharmaceuticals market by value in 2016?
- What will be the size of the Indonesia pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the Indonesia pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Indonesia's pharmaceuticals market?

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
- The Indonesian pharmaceuticals market had total revenues of $7.2bn in 2016, representing a compound annual growth rate (CAGR) of 8.8% between 2012 and 2016.
- Some impetus market growth can be attributed to the introduction of reimbursement programs, such as Jamkesmas and the Family Hope Program (Program Keluarga Harapan (PKH), which increased access to medicines and insurance coverage from 26.1% in 2007, to 65% in 2011.
- The Indonesian market is still controlled by domestic companies that hold 70% of the market share compared to the 30% owned by multinationals.